Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients

Nephrology Dialysis Transplantation

Volumn 11, Issue 2, 1996, Pages 347-351

  Verpooten, G A ^a   Cools, F J ^a   Van Der Planken, M G ^a   Bedert, L C ^a   Claes, R ^a   Van Gaal, L F ^a   De Broe, M E ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cholesterol; Cyclosporin; Fibrinolysis; Lipids; Plasminogen activator inhibitor; Renal allograft recipients

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENICITY;

EID: 0030026771     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027265     Document Type: Article

References (29)

1. Vanrenterghem Y, Roels L, Lerut T et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; 1: 999-1002
2. Nachman RL. Thrombosis and atherogenesis; molecular connections. Blood 1992; 79: 1897-1906
3. Vague P, Raccah D, Juhan-Vague I. Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis Metabolism 1992; 41 [Suppl 1]: S2-S6
4. Kannel WB Lipids, diabetes, and coronary heart disease, insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107
5. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9
6. Ley CJ, Swan J, Godsland IF, Walton C, Crook D, Stevenson JC. Insulin resistance, lipoproteias, body fat, and hemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. J Am Coll Cardiol 1994; 23: 377-383
7. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992; 11: 291-311
8. Levi M, Wilmink J, Büller HR, Surachno J, ten Cate JW. Impaired fibrinolysis in cyclosporin-treated renal transplant patients. Transplantation 1992; 54: 978-983
9. Juhan-Vague I, Vague P, Alessi MC et al. Relationship between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13: 331-336
10. Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 39 [Suppl 31]: S24-S28
11. Edwards BD, Bhatnagar D, Mackness MI et al. Effect of low dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Q J Med 1995; 88: 109-113
12. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporin-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868-871
13. Irish AB, Hayes JM, Simons LA, Simons J, Savdie E. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992, 22: 243-248
14. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Does cyclosporin increase hpoprotein(a) concentrations in renal transplant recipients? Lancet 1993; 341: 268-270
15. Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics 1978; 34: 469-474
16. Vercaemst RA, Union A, Rosseneu M, De Craene I, De Backer G, Kornitzer M. Quantification of plasma free cholesterol and cholesteryl esters by high performance liquid chromatography. Study of a normal population. Atherosclerosis 1989; 78: 245-250
17. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of upoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986, 74: 758-765
18. Black IW, Wilcken DEL. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992; 38: 353-357
19. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC, Lp(a) lipoprotein in patients with chronic renal failure treated by haemodialysis. Clin Chem 1987; 33: 721
20. Karádi I, Romics L, Pálos G et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35: 2121-2123
21. Raine AEG, Carter R, Mann JI, Chapman JR, Morris PJ. Increased plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression. Transplant Proc 1987; 19: 1820-1821
22. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasmalipoproteins in heart and liver transplant patients. Transplant Proc 1985; 17: 1997-2002
23. Lopez-Miranda J, Vilella E, Péréz-Jiminéz F et al. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 1993; 42: 678-683
24. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984; 4: 357
25. Sutherland WHF, Walker RJ, Ball MJ, Stapley SA, Robertson ML. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995; 48: 227-236
26. Tremoli E, Camera M, Maderna P et al Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. A LDL receptor-independent phenomenon. Arterioscler Thromb 1993; 13: 338-346
27. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89: 7422-7426
28. Cohen H, Neild GH, Patel R, Mackie IJ, Machin SJ. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res 1988; 49: 91
29. Mussoni L, Mannucci L, Sirtori M et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arteriosclerosis Thromb 1992; 12: 19-27